VRAX Company Profile and Key Details

Q: Who are the executives of VRAX?

Ms. Lily FuHead of Supply ChainMr. James FosterChairman & Chief Executive OfficerMr. Mark James TernouthChief Technical OfficerDr. Tomasz Evan GeorgeChief Scientific OfficerMr. Cameron Lee ShawChief Operating Officer & DirectorMr. Jason D. DavisChief Financial OfficerMr. James WangHead of Procurement & SourcingMr. Clement MonteilHead of Scientific R&D

NASDAQ : VRAX

Virax Biolabs Group

$0.24

0.0815+53.09%

At Close 4:00 PM

$0.28

+0.0408+17.36%

After-Market 08:30 PM

62.89

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Virax Biolabs Group Limited (VRAX) stock surged +53.09%, trading at $0.24 on NASDAQ, up from the previous close of $0.15. The stock opened at $0.30, fluctuating between $0.23 and $0.53 in the recent session.

Stock Snapshot

0.1535

Prev. Close

1.02M

Market Cap

0.226

Day Low

-0.19

P/E Ratio

-1.22

EPS (TTM)

-3.51

Cash Flow per Share

0.3

Open

4.34M

Number of Shares

0.5335

Day High

84.66%

Free Float in %

3.57

Book Value

760.22M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 18, 2026	0.30	0.53	0.23	0.24	760.67M
May 15, 2026	0.14	0.16	0.14	0.15	1.69M
May 14, 2026	0.13	0.15	0.13	0.14	1.18M
May 13, 2026	0.14	0.15	0.13	0.14	1.74M
May 12, 2026	0.15	0.16	0.14	0.14	2.02M
May 11, 2026	0.17	0.19	0.14	0.15	10.77M
May 08, 2026	0.15	0.17	0.14	0.17	20.41M
May 07, 2026	0.13	0.14	0.13	0.14	2.74M
May 06, 2026	0.12	0.13	0.12	0.13	1.44M
May 05, 2026	0.13	0.13	0.12	0.12	827.14K
May 04, 2026	0.13	0.14	0.13	0.13	1.7M
Apr 30, 2026	0.13	0.13	0.12	0.13	799.96K
Apr 29, 2026	0.13	0.14	0.13	0.14	465.88K
Apr 28, 2026	0.14	0.14	0.13	0.13	2.04M
Apr 27, 2026	0.15	0.15	0.14	0.14	957.12K
Apr 23, 2026	0.13	0.18	0.13	0.16	10.18M
Apr 22, 2026	0.14	0.14	0.13	0.14	1.42M
Apr 21, 2026	0.14	0.14	0.12	0.13	2.26M
Apr 20, 2026	0.14	0.15	0.14	0.14	1.82M
Apr 17, 2026	0.15	0.15	0.13	0.15	3.14M

Contact Details

London, W1F 8LX

United Kingdom

https://viraxbiolabs.com 442 077 887414

About Company

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name, as well as infrared thermometers, pulse oximeters, masks, gloves, and other PPE products. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, individual consumers, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.

Stock Peers

ARGX

-23.06-2.88%

argenx SE$776.26 REGN

-68.57-9.82%

Regeneron Pharmaceuticals, Inc.$629.68 UTHR

-1.59-0.28%

United Therapeutics Corporation$566.99 MDGL

-1.46-0.28%

Madrigal Pharmaceuticals, Inc.$522.23 VRTX

-0.37-0.08%

Vertex Pharmaceuticals Incorporated$436.58 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-22.05-6.44%

Praxis Precision Medicines, Inc.$320.53 KRYS

-14.54-4.75%

Krystal Biotech, Inc.$291.75 ALNY

-0.71-0.25%

Alnylam Pharmaceuticals, Inc.$286.27 ASND

-2.86-1.19%

Ascendis Pharma A/S$237.64

Company Overview

Virax Biolabs Group Limited (NASDAQ:VRAX) closed at $0.23 USD, gaining $0.08 (53.09%) from the previous close of $0.15. The stock is currently mid-range between its 52-week high and low $0.10 and $1.19. With a market capitalization of about $1.02 million, Virax Biolabs Group Limited is classified as a micro-cap and shows market-like volatility (beta ~1.05). Key stats such as the average daily volume over the past year has been around 26.62 million shares, trading with heavier-than-usual volume. Headquartered in London, None, Virax Biolabs Group Limited operates in the Healthcare sector and the Biotechnology industry. Led by CEO James Foster, the company employs approximately 17 people and listed since July 21, 2022. Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology.

Technical Performance

VRAX has shown weak momentum, losing -16.37% over the past week and -53.01% over the past quarter, though year-to-date performance is down -17.29%. Short-term trend indicators are bullishly aligned (SMA20 -4.69%, SMA50 -26.25%, SMA200 -64.35%). The stock’s 14-day RSI is 41.03 (neutral), while the ATR of 0.03 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -88.05% below its high and over 10.56% above its low. Average 10-day trading volume of 114.07 million shares is significantly above the 3-month average of 26.75 million, indicating heightened recent market interest.

Valuation Metrics

Virax Biolabs Group Limited trades at a P/E ratio of -0.2, slightly below the S&P 500 average, with a price-to-sales ratio of 352.77 and a price-to-book ratio of 0.22 suggesting the stock is closer to book value. The P/FCF stands at -0.17, also above market averages.

Dividend & Fair Value

Virax Biolabs Group Limited last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.23. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Virax Biolabs Group Limited generated EPS of -$1.25 over the past year. Five-year average earnings growth is -21.07%. Wall Street analysts project EPS growth of 57.19% annually over the next five years. The latest quarter delivered EPS of -$0.76. The next quarter is forecast at -$0.10. Next year's EPS is expected at $68.42. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $3.00 to $3.00. The high target offers 1204.35% upside. The low target suggests 1204.35% downside. The mean target is $3.00. This offers 1204.35% upside. Virax Biolabs Group Limited earnings surprise history is a mixed track record. The quarter that ended November 01, 2025, missed forecasts by 123.08%.

Shareholding & Insider Activity

Virax Biolabs Group Limited has 4.34 million shares outstanding. The public float is 3.68 million shares, elevated short interest at 8.99% of float. This equals 350.86 thousand shares. The short ratio is 0.31 days. Institutional investors hold 4.39% of the float. Insiders own 1.79%.

Financial & Profitability Overview

Over the trailing twelve months, Virax Biolabs Group generated $6.33K in revenue, or $0.00 per share. Gross margin was -838.21%, operating margin -97344.76%, and net profit margin -95739.17%. Returns are negative, with ROA at -94.31% and ROE at -106.41%.
On valuation metrics, Virax Biolabs Group trades at a P/E of -0.20, P/S of 352.77 and P/B of 0.22. The current ratio is 11.35 and quick ratio is 11.21. Operationally, the company’s inventory turnover is 4.89 and cash conversion cycle is 21492.96 days. Debt-to-equity is 0.10, supported by a cash flow-to-debt ratio of -10.35.

Quarterly Financial Highlights

For the quarter ended Mar 31, 2025, Virax Biolabs Group posted revenue of $6.33K, down slightly from $156.42K in the prior quarter. Gross profit was - $53.07K (margin -838.21%). Operating income was - $6.16M (margin -97344.8%). Net income was- $6.06M (EPS - $1.96).
The company ended the quarter with $4.23M in cash and short-term investments, a total debt of $377.00K, and net debt of - $3.85M. Total assets were $6.43M, with equity of $5.46M. Financials further reflected weakness, with operating cash flow of - $4.56M, free cash flow of - $5.17M, and capital expenditures of - $603.89K.

Price Forecast & Outlook

Our AI price prediction model suggests that Virax Biolabs Group Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -19.15%, with price expected at $0.19 by June 01, 2026, within a range of $0.16 to $0.22 3-Month Outlook: Projected fall of -82.98%, reaching $0.04 by August 13, 2026, with a range of $0.00 to $0.08. 1-Year Outlook: Projected loss of -74.47%, with price at $0.06 by May 18, 2027, within a range of $0.00 to $0.16.

Key Takeaways

Virax Biolabs Group Limited (NASDAQ:VRAX) shares are down -17.29% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Virax Biolabs Group Limited trading at a premium to the broader market with a P/E of -0.2. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $3.00, suggesting 1176.6% upside. Our AI forecast model points to short-term weakness (-19.15% over two weeks), a medium-term fall (-82.98% over three months), and a longer-term loss (-74.47% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Virax Biolabs Group Limited (VRAX) stock price?

Virax Biolabs Group Limited (NASDAQ: VRAX) stock price is $0.24 in the last trading session. During the trading session, VRAX stock reached the peak price of $0.53 while $0.23 was the lowest point it dropped to. The percentage change in VRAX stock occurred in the recent session was 53.09% while the dollar amount for the price change in VRAX stock was $0.08.

VRAX's industry and sector of operation?

The NASDAQ listed VRAX is part of Biotechnology industry that operates in the broader Healthcare sector. Virax Biolabs Group Limited designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of VRAX?

Ms. Lily Fu
Head of Supply Chain
Mr. James Foster
Chairman & Chief Executive Officer
Mr. Mark James Ternouth
Chief Technical Officer
Dr. Tomasz Evan George
Chief Scientific Officer
Mr. Cameron Lee Shaw
Chief Operating Officer & Director
Mr. Jason D. Davis
Chief Financial Officer
Mr. James Wang
Head of Procurement & Sourcing
Mr. Clement Monteil
Head of Scientific R&D

How VRAX did perform over past 52-week?

VRAX's closing price is 135% higher than its 52-week low of $0.10 where as its distance from 52-week high of $1.19 is -80.25%.

How many employees does VRAX have?

Number of VRAX employees currently stands at 17.

Link for VRAX official website?

Official Website of VRAX is: https://viraxbiolabs.com

How do I contact VRAX?

VRAX could be contacted at phone 442 077 887414 and can also be accessed through its website. VRAX operates from 30 Broadwick Street, London, W1F 8LX, United Kingdom.

How many shares of VRAX are traded daily?

VRAX stock volume for the day was 760.22M shares. The average number of VRAX shares traded daily for last 3 months was 26.62M.

What is the market cap of VRAX currently?

The market value of VRAX currently stands at $1.02M with its latest stock price at $0.24 and 4.34M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	17
Beta	1.6
Sales or Revenue	$6.33K
5Y Sales Change%	-0.977%
Fiscal Year Ends	March
Sector	Healthcare
Industry	Biotechnology

VRAX Company Profile and Key Details

Virax Biolabs Group

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Key Takeaways

Price Forecast & Outlook

Financial & Profitability Overview

Quarterly Financial Highlights